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Cell-Active Dual Specificity Phosphatase
Inhibitors Identified by High-Content Screening
icity in several cell types, including human hepatoma
cells [5]. Thus, inhibitors of phosphatases that dephos-
phorylate MAPK may exhibit growth inhibitory activity in
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1Department of Pharmacology cancer cells by perturbing the timing of Erk activation [2].
There is strong evidence for a role of DSPases in2 Department of Chemistry
University of Pittsburgh cancer. Members of the Cdc25 family were found over-
expressed in a variety of human tumors (reviewed inPittsburgh, Pennsylvania 15261
[6]), and both Cdc25A and Cdc25B have oncogenic
properties [7]. Evidence for an involvement of MKPs in
oncogenesis comes from studies reporting overexpres-
sion of MKP-1 (CL-100) in prostate [8], breast [9], and
Summary ovarian cancer, where its expression level was also cor-
related with decreased progression-free survival [10].
Phosphorylation of extracellular signal-regulated ki- Cell-active, selective DSPase inhibitors would therefore
nase (Erk) is tightly controlled by dual specificity phos- not only be valuable tools to help dissect the complex
phatases (DSPases), but few inhibitors of Erk dephos- regulatory processes involved in the attenuation of Erk
phorylation have been identified. Using a high-content, activation, but might also find applications as novel tar-
fluorescence-based cellular assay and the National get-based antineoplastic therapies. While a few potent
Cancer Institute’s 1990 agent Diversity Set, we identi- and selective Cdc25 inhibitors have been identified [11,
fied ten compounds (0.5%) that significantly increased 12], inhibitors of MKPs have not been reported to date.
phospho-Erk cytonuclear differences in intact cells. Current efforts directed at phosphatase drug discov-
Three of the ten positive compounds inhibited the mi- ery encompass different strategies such as rational drug
togen-activated protein kinase phosphatase-3 (MKP- design [13] or in vitro chemical library screening on a
3/PYST-1) in vitro without affecting VHR or PTP1B larger scale [12]. Cell functions are, however, comprised
phosphatases. The most potent inhibitor of MKP-3 had of many interconnecting signaling and feedback path-
an IC50 of 10 M and inhibited MKP-3 in a novel, ways, and in vitro analyses based on isolated targets
fluorescence-based multiparameter chemical com- do not address this complexity. In addition, in vitro
plementation assay. These results suggest that the assays do not provide information about physicochemi-
phospho-Erk nuclear accumulation assay may be a cal parameters that determine whether a compound has
useful tool to discover DSPase inhibitors with biologi- the ability to penetrate cellular membranes. In contrast,
cal activity. target-based cellular assays would identify only those
compounds that enter cells. Here we report for the first
time the use of a high-content, cell-based assay in theIntroduction
discovery of cell-active DSPase inhibitors. We analyzed
the NCI Diversity Set, which is a computationally se-Dual-specificity phosphatases are intracellular enzymes
lected subset of the NCI compound repository (de-that catalyze the removal of phosphate groups from
scribed in [11]), for phospho-Erk nuclear accumulationthreonine and tyrosine residues on the same protein
as an endpoint consistent with inhibition of either Cdc25substrate. Key enzymes that are tightly regulated by
or MKPs in intact cells. We found that compounds withDSPases are the cyclin-dependent kinases, which are
Erk-activating activity were enriched for in vitro Cdc25dephosphorylated by members of the Cdc25 family and
inhibitors. We then examined the selectivity of newlycontrol cell cycle progression, and mitogen-activated
identified agents against Cdc25-related phosphatasesprotein kinases (MAPK), which are dephosphorylated
and identified one compound that inhibited MKP-3 butby MAPK phosphatases (MKPs) and have a pivotal role
not the protein tyrosine phosphatase PTP1B or the pro-in mitogenic signal transduction, survival, stress re-
totype DSPase VHR. Finally, we developed a novel mul-sponse, and programmed cell death. The activation of
tiparametric, fluorescence-based assay that specificallyMAPK pathways by upstream kinases and cell surface
measured MKP-3 activity in intact cells and used it toreceptor-mediated events have been studied exten-
demonstrate inhibition of MKP-3 in whole cells. The re-sively. In contrast, the events that regulate termination
sults demonstrate the utility of a target-based cellularof MAPK signaling are less well understood, although
screen for phospho-Erk nuclear accumulation as a toolit is clear that MKPs play a major role [1]. There is also
in the discovery of cell-active DSPase inhibitors.some evidence that activation of Erk, a member of the
MAPK family, is regulated by the cell cycle phosphatase
Cdc25A [2], possibly by affecting the tyrosine phosphor-
Resultsylation status and activity of Raf-1 [3]. A growing body
of evidence suggests that prolonged activation of the
Erk Activation by Submicromolar Cdc25 InhibitorsErk pathway can lead to cell cycle arrest [4] and cytotox-
Because we had previously shown that the Cdc25 inhibi-
tor Compound 5 (NSC 672121) possessed Erk-activating
activity [2], we asked whether Erk activation was a gen-*Correspondence: lazo@pitt.edu
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Figure 1. A Targeted Library of Cdc25 Inhibitors Is Enriched for Erk Activators
A focused library of 36 compounds with submicromolar activity against Cdc25B2 was analyzed for nuclear phospho-Erk accumulation on the
ArrayScan II.
(A) Cytonuclear difference values from two individual multiwell plates (open and closed squares) were calculated for each compound.
Compounds whose average cytonuclear difference values (crosses) were greater than 2-fold over vehicle control (solid line) were scored as
positives. Seven compounds out of 36 (19.5%) were positives and are labeled with identifiers.
(B) Background-corrected cytonuclear difference values from wells treated with compounds at 10 M were plotted against their IC50 values
for Cdc25B2 inhibition. Five of the most active Cdc25 inhibitors were found in the top 30th percentile of Erk accumulators (boxed).
eral feature of compounds with Cdc25 inhibitory activity. difference values greater than 2-fold over background
(Figure 1A). Figure 1B shows that, while there was noThirty-six agents, 22 of which were members of a pre-
direct correlation among the compounds’ phospho-Erkviously evaluated 10,070 compound set from the NCI
accumulating ability and their inhibitory activity againstrepository [12] plus 14 synthetic analogs, which we pre-
Cdc25 in vitro, several of the most potent Erk activatorsviously found were potent in vitro inhibitors of Cdc25
were clustered in the top 30th percentile of in vitro Cdc25(IC50 values  1 M) [11, 12], were analyzed for nuclear
inhibitory activity. We therefore hypothesized that phos-phospho-Erk accumulation. NIH3T3 cells were treated
pho-Erk nuclear accumulation might be a surrogate end-in duplicate 96-well microplates for 20 min with com-
point for Cdc25 inhibition.pounds or vehicle, fixed, and stained with an anti-phos-
pho-Erk antibody. Images were acquired on a Cellomics
ArrayScan II, an automated batch image acquisition and A High-Content Screen for Erk-Activating
analysis system, using the previously described nu- Compounds in Intact Mammalian Cells
cleus-to-cytoplasm translocation algorithm [2]. Of the We then examined the members of the publicly available
NCI Diversity Set, a computationally selected subset36 compounds analyzed, seven (19.5%) had cytonuclear
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Table 1. Selection Statistics for Compounds that Caused Nuclear Accumulation of Phospho-Erk in Mammalian Cell-Based High-Content
Screen
Number of Compounds
% of Initial Positive Compounds % of NCI Diversity Set
Total number of compounds 1990 (100%)
Positive compounds for phosopho-Erk nuclear accumulation 34 (1.7%)a
Artifacts 24 (1.2%)
Rounding 5 (15%)
Toxicity 8 (24%)
Analysis 9 (26%)
Autofluorescence 2 (6%)
Remaining positive compounds 10 (29%) 10 (0.5%)
Microscopically confirmed 10 (29%)
Bona fide number of positive compounds 10 (0.5%)
a Based on the average cytonuclear difference values from two independent experiments.
of the National Cancer Institute’s compound repository nuclear difference values caused by some compounds
were not exclusively due to protein translocation, but[11], for their ability to increase nuclear accumulation of
phosphorylated Erk in intact mammalian cells. Table 1 resulted from an increase in overall phospho-Erk levels.
shows the selection statistics for compounds causing
phospho-Erk nuclear accumulation. The vast majority of
compounds did not affect Erk phosphorylation. Agents In Vitro Phosphatase Inhibition Studies
MKP-3, Cdc25A, and VHR have been reported to medi-that caused a greater than 2-fold increase over the aver-
age cytonuclear differences from all 1990 compounds ate Erk dephosphorylation. Therefore, we analyzed all
positive compounds for in vitro inhibition of MKP-3,were scored as positives. Using these criteria, we identi-
fied 34 compounds as positive, an initial “hit rate” of Cdc25A, VHR, and the tyrosine phosphatase PTP1B. At
the highest concentration tested (10 M), three com-1.75%. Visual examination of the archived immunofluo-
rescence images confirmed elevated nuclear phospho- pounds (NSC 45382, NSC 295642, and NSC 357756)
inhibited MKP-3 (PYST-1) by 50% or more, and threeErk levels for ten of the initial positive compounds (not
shown). The remaining 24 compounds were classified (NSC 310551, NSC 295642, and NSC 321206) inhibited
the catalytic domain of Cdc25A (Table 2). None of theas artifacts of various types (Table 1). Thus, the bona
fide percentage of positive compounds in the intact compounds showed significant inhibition of full-length
Cdc25B, but two (NSC 295642 and NSC 321206) weremammalian cell screen was 10/1990, or 0.5%.
An increase in cytonuclear difference values is indica- active against a truncated form of Cdc25B lacking the
regulatory N terminus. All compounds were devoid oftive of Erk activation through phosphorylation, translo-
cation, or both. We therefore examined the frequency activity against the prototype DSPase, VHR, or the pro-
tein tyrosine phosphatase, PTP1B. The most active com-distributions of cytonuclear and cytoring intensities in
the entire cell population for each well to determine pound against MKP-3, NSC 357756, inhibited MKP-3 with
an IC50 of 8.0 M and appeared to be selective for MKP-3the relative contributions of cytoplasmic and nuclear
fluorescence intensities to the cytonuclear difference over all other phosphatases tested. Western blot analy-
sis on whole-cell lysates from cells treated with com-values. Figure 2 shows that all compounds increased
Erk phosphorylation in both the cytoplasm and in the pounds that had antiphosphatase activity confirmed the
results from the immunofluorescence-based screen.nucleus. While most compounds caused a more pro-
nounced increase in nuclear pErk, some of them showed Figure 3 shows that the five compounds that inhibited
either MKP-3, Cdc25A, or both caused an increase insimilar increases in cytoplasmic and nuclear phospho-
Erk intensities. Thus, the increases in phospho-Erk cyto- total cellular Erk phosphorylation that was comparable
Figure 2. Relative Changes in Cytoplasmic
versus Nuclear pErk Levels in Cells Treated
with Visually Confirmed Positive Compounds
in the NCI Diversity Set
Nuclear and cytoplasmic phospho-Erk inten-
sities were retrieved from archived image
analysis data for all ten positive compounds
from the phospho-Erk nuclear accumulation
screen. All positive compounds caused both
an increase in cytoplasmic and in nuclear
phospho-Erk intensity. Data are the average
cytoplasmic (hatched) or nuclear (solid bars)
intensities of 326 to 560 cells  SEM and
presented as the average fluorescence inten-
sity increase over vehicle-treated control.
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Table 2. In Vitro Phosphatase Inhibition by Erk Activators
Percent Inhibition at 10 M
NSC MKP-3a,b Cdc25Ba,b Cdc25Ab,c Cdc25Bb,c VHRd PTP1Bd
112200 inactive inactive 47  3 inactive inactive inactive
310551 15  3 18  2 54  43 12  3 inactive inactive
7215 33  6 22  4 49  4 inactive inactive inactive
45382 53  6 28  15 36  4 inactive inactive inactive
118176 13  3 23  8 32  4 inactive inactive inactive
295642 50  3 21  8 74  2 61  7 inactive inactive
294526 inactive inactive 35  4 inactive inactive inactive
321206 45  4 36  6 72  6 87  3 inactive inactive
357756 64  4 20  7 inactive 19  4 inactive inactive
359449 inactive inactive 21  6 inactive inactive inactive
Inactive indicates less than 10% inhibition.
a Full-length His6-tagged protein.
b Minimum of three independent determinations  SD.
c Catalytic domain.
d Full-length GST fusion protein.
to or greater than that of the previously described Cdc25 nones, one of them (NSC 45382) being closely related
to NSC 663284, one of the two most potent in vitro Cdc25inhibitor, Compound 5 (NSC 672121).
inhibitors described to date [11], thereby validating the
quinone structure as a pharmacophore for Cdc25 inhibi-Structural Comparisons
Figure 4 shows the structures of Erk-activating com- tion. Four compounds were transition metal complexes,
among them the two compounds (NSC 295642 and NSCpounds. Two of the ten positive compounds were qui-
321206) that possessed the highest Cdc25A inhibitory
activity. The most active MKP-3 inhibitor, NSC 357756,
was structurally unrelated to any of the other com-
pounds.
NSC 357756 Inhibits MKP-3 in Whole Cells
Because of the lack of confirmed MKP-3 inhibitors, we
developed a multiparameter fluorescence-based cellu-
lar assay based on our previously described “chemical
complementation” strategy [2] to determine whether NSC
357756 was able to inhibit MKP-3 in intact cells. HeLa
cells were transfected with a c-myc-tagged version of
MKP-3 and stimulated with 12-O-tetradecanoylphorbol
13-acetate (TPA) to generate a strong phospho-Erk sig-
nal that was distributed as uniformly as possible through-
out the entire cell population. Cells were then stained
simultaneously with anti-phospho-Erk and anti-c-myc
antibodies, followed by Alexa 546- and Alexa 488-conju-
gated secondary antibodies to visualize phospho-Erk
and c-myc-MKP-3, respectively. Fluorescence images
acquired with TRITC and FITC compatible filter sets
revealed that none of the MKP-3-expressing cells re-
sponded to TPA with increased Erk phosphorylation
(Figure 5A). Expression of the phosphatase-inactive
green fluorescent protein (GFP) did not affect the cells’
responsiveness to TPA (data not shown). Inclusion of the
broad-spectrum PTPase inhibitor, phenylarsine oxideFigure 3. Western Blot Analysis for Phosphorylated Erk in Com-
(PAO, 50 M), completely restored responsiveness topounds with Anti-MKP-3 or Cdc25A Activity
TPA in MKP-3-expressing cells (Figure 5B). PAO (10M)(A) Cells were treated with 10 M of compounds or vehicle for 20
min and lysed, and lysates were immunoblotted with anti-phospho- and NSC 357756 (10 M) partially reversed the MKP-3-
Erk or anti-Erk antibodies, respectively. induced loss of phospho-Erk in the cells that stained
(B) Phospho-Erk bands were scanned by densitometry and intensit- positive for MKP-3 (Figures 5C and 5D).
ies normalized to total Erk. Data are from a single experiment that c-myc-MKP-3 (FITC) and pErk (TRITC) levels were
has been repeated with similar results and are presented as fold
then quantitated in approximately 4000 individual cellsincrease over vehicle control. Lane 1, DMSO (vehicle); lanes 2–7,
by automated image analysis on the ArrayScan II. First,Compound 5 (NSC 672121), NSC 350551, NSC 45382, NSC 295642,
NSC 321206, and NSC 357756, respectively. the number of MKP-3 expressors was determined for
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Figure 4. Structures of Erk Activators from
the Cell-Based Screen
each condition by choosing appropriate intensity cutoff mental Therapeutics Program website (http://dtp.nci.
nih.gov/webdata.html). We therefore mined the NCI’svalues from FITC (Alexa 488) intensity distribution histo-
grams. Based on this method, we found transfection web-accessible database for antitumor activity in mice
using the compounds that were positive for phospho-efficiencies of 6% to 23% for MKP-3 and 53% for GFP.
We then determined average nuclear phospho-Erk in- Erk nuclear accumulation. Using an increased survival
time of 135% over untreated control (T/C  135%) astensities in the two cell subpopulations. Figure 6 shows
the differences in nuclear phospho-Erk intensities be- an accepted standard for significant antitumor activity,
we found that NSC 357756 had activity against P388tween cell subpopulations that did or did not express
MKP-3 or GFP. We found that in GFP-expressing cells, leukemia (T/C  139% at 25 mg/kg/dose, 6/6 animals
surviving), L1210 leukemia (T/C  178% at 18 mg/kg/there was little difference in phospho-Erk levels after
TPA stimulation whether cells expressed GFP or not dose, 6/6 animals surviving), and M5076 sarcoma (T/C
137% at 50 mg/kg/dose, 8/10 animals surviving). A sec-(Figure 6). The small increase in phospho-Erk intensities
in GFP-expressing cells, which manifested itself as a ond positive compound from the screen, namely NSC
295642, had activity against P388 leukemia (T/C 136%negative difference between the two cell populations,
was due to spectral overlap between the two fluoro- at 3.12 mg/kg/dose, 6/6 animals surviving).
phores. In contrast, cells transfected with MKP-3 and
treated with TPA showed significantly lower levels of Discussion
nuclear phospho-Erk specifically in the MKP-3 express-
ing cells (Figure 6), consistent with the images shown Advances in genomics research, combinatorial chemis-
in Figure 5A. The broad spectrum PTPase inhibitor, phe- try, and laboratory automation have made it possible to
nylarsine oxide (PAO), restored responsiveness to TPA interrogate large compound collections in a short period
in MKP-3-expressing cells as evidenced by a concentra- of time. High-throughput screening has therefore be-
tion-dependent decrement in pErk differences between come a main component of contemporary drug discov-
MKP-3 expressing and nonexpressing subpopulations, ery. The vast majority of these screens are based on in
indicating that PAO inhibited MKP-3 in the cell. A con- vitro assays, which have the advantage of being ultra-
centration of 50 M PAO reduced pErk level differences high-throughput but do not take into consideration other
to those seen in cells transfected with GFP. Inclusion parameters, for example, physicochemical properties
of the putative MKP-3 inhibitor, NSC 357756, resulted that determine drug-like behavior such as cell perme-
in a partial rescue of TPA responsiveness that was com- ability. Furthermore, target-based screening assays
parable in magnitude to that seen with 5 to 10 M PAO. may not be predictive of drug effect within the context
of the whole cell [15]. Thus, attempts have been made
to incorporate cell-based screens into the early stagesNSC 357756 Has Antitumor Activity In Vivo
In vivo antitumor data against a variety of tumors have of the drug discovery process to select for compounds
with cellular activity. Examples include screening ofbeen generated by the National Cancer Institute for
many of the compounds in the NCI compound repository yeast strains for DNA damaging agents [16], A-549 lung
cancer cells for inhibitors of motor proteins by Western[14]. These results are publicly available on the Develop-
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Figure 5. A Fluorescence-Based Chemical
Complementation Assay
HeLa cells were transfected in 384-well plates
with cDNAs encoding c-myc-tagged MKP-3
as described in Experimental Procedures.
Twenty-four hours after transfection, cells
were treated for 15 min with TPA (500 ng/ml)
in the absence or presence of phenylarsine
oxide (PAO) or NSC 357756 and immuno-
stained with anti-c-myc and anti-phospho-
Erk antibodies. Nuclei were counterstained
with Hoechst 33342. Right, nuclei and MKP-3;
left, phospho-Erk.
(A) TPA only, (B) 50 M PAO, (C) 10 M PAO,
(D) 10 M NSC 357756.
blot analysis of phospho-nucleolin [17], and a morpho- Here we have for the first time investigated the utility
of a target-based cellular screen to identify compoundslogical differentiation screen in C2C12 muscle cells for
tubulin disrupting agents [18]. Most of these screens that caused nuclear accumulation of phosphorylated
Erk. Based on the well-established role for MKPs inare single-parameter phenotypic assays in whole cell
populations. Erk deactivation [1] and on our previously published
observation that ectopic expression of Cdc25A causedHigh-content screening is a recently introduced analy-
sis tool designed to yield information about the activity a decrease in Erk phosphorylation [2], we hypothesized
that nuclear phospho-Erk accumulation would repre-and spatial regulation of multiple targets in individual
cells rather than in a cell population as a whole [19, 20]. sent a suitable intracellular target marker for compounds
with dual-specificity phosphatase activity. Using theDue to the novelty of this concept, a shortage of suitable
assays, and the instrumentation necessary to perform previously described nuclear translocation assay on an
Cellomics ArrayScan II solid-phase cytometer [2, 21],them in a high-throughput format, however, little infor-
mation exists in the literature about the outcomes of we obtained information about both Erk phosphorylation
status and subcellular localization after short-term treat-high-content drug discovery screens in intact mamma-
lian cells. ment of NIH3T3 cells with the NCI Diversity Set, a pre-
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phorylation levels, even when measured on specific tar-
get proteins, are a readout consistent with an alteration
in either kinase or phosphatase activity, they do not
yield information about target specificity.
We therefore devised a fluorescence-based, multi-
parametric variant of our previously described chemical
complementation assay [2, 11] to confirm that NSC
357756 inhibited MKP-3 in whole cells. This assay is
based on the selective measurement of Erk phosphory-
lation in MKP-3 expressing and nonexpressing cell
subpopulations in the presence or absence of the com-
pound of interest. Immunofluorescence images pre-
sented by Brunet et al. [26] had indicated that MKP-3
expressing CCL-39 cells did not respond to serum stim-
ulation with enhanced Erk phosphorylation. Consistent
with their data, we found that, in a transiently transfected
Figure 6. Quantitation of Nuclear Phospho-Erk Levels in MKP-3 Ex- and TPA-stimulated HeLa cell population, cells that ex-
pressing and Nonexpressing Cell Subpopulations pressed MKP-3 appeared to have significantly lower
The identical 384-well plate described in the legend to Figure 5 pErk levels than those not expressing MKP-3. We then
was scanned at excitation/emission wavelengths of 350/461 nm used automated batch image acquisition and analysis
(Hoechst), 494/519 nm (Alexa 488), and 556/573 nm (Alexa 546) on
to simultaneously quantitate MKP-3 expression and nu-the ArrayScan II using the general screening application. Approxi-
clear phospho-Erk levels in approximately 4000 individ-mately 1000 individual cells from each well were simultaneously
ual cells. Cells were gated into expressing or nonex-analyzed for phospho-Erk, c-myc-MKP-3, and GFP intensities. Cells
were separated into MKP-3 (GFP) expressing and nonexpressing pressing cell subpopulations based on MKP-3 label
subpopulations by setting appropriate gates in the FITC (Alexa 488) intensity, and phospho-Erk intensities were averaged
channel, and average nuclear phospho-Erk intensities were calcu- from both subpopulations. We found that there was a
lated for MKP-3 (GFP) expressors and nonexpressors. Bars repre-
consistent, quantifiable, and significant difference insent the average difference in nuclear phospho-Erk intensities be-
phospho-Erk levels in cells that did or did not expresstween nonexpressing and MKP-3 (GFP)-expressing subpopulations
MKP-3. In contrast, cells expressing phosphatase-inac-from quadruplicate wells. Data are from a single experiment that
has been repeated with similar results. tive GFP had phospho-Erk levels similar to or higher
than cells not expressing GFP. The difference in nuclear
phospho-Erk intensities between the two subpopula-
viously described compound library selected for maxi- tions was fully abrogated in the presence of 50 M
mal chemical diversity. This screen identified ten phenylarsine oxide, and partially abrogated in the pres-
compounds as positives, a 0.5% “hit rate.” ence of 10 M and 20 M NSC 357756, indicating that
In vitro phosphatase studies using recombinant pro- NSC 357756 had the ability to inhibit MKP-3 in the cell.
teins and the small molecule substrate OMFP revealed We are currently expanding the scope of this assay to
that, of the ten positive compounds identified from the investigate whether NSC 357756 inhibits other MKPs or
screen, three (30%) inhibited MKP-3 by more than 50% the various Cdc25 isoforms.
at 10M. Three compounds had activity against Cdc25A By choosing the NCI Diversity Set, we exploited sub-
catalytic domain. The most potent inhibitor of MKP-3, stantial information readily available from the NCI Devel-
NSC 357756, had an IC50 of 8.0 M, making it the first opmental Therapeutics Program about the in vivo antitu-
low micromolar MKP-3 inhibitor reported to date. None mor activity of this library against various tumors.
of the positives inhibited VHR, which has also been Antitumor data in a variety of mouse models have been
reported to dephosphorylate Erk [22]. This was of inter- archived for seven of the ten positives identified in the
est because the active site in all DSPases and in phospho-Erk accumulation screen. Of these seven com-
PTPases has the same signature motif [23] and because pounds, two had significant activity against at least one
VHR is a prototype DSPase that has substantial similar- tumor type. In contrast, among 14 submicromolar inhibi-
ity to both Cdc25 [24] and MKP-3 [25]. These data sug- tors of Cdc25, which were identified from a much larger
gest that it may be possible to generate selective inhibi- subset of the NCI compound repository [12], none had
tors of these highly related enzymes. activity in vivo. Although the sample size we are analyz-
The investigation of whether NSC 357756 had the abil- ing is small, the data are consistent with the notion that
ity to inhibit MKP-3 in whole cells necessitated the devel- cell-based screens may be biased toward the identifica-
opment of a novel assay system for cellular MKP-3 activ- tion of biologically active agents. It is also interesting to
ity. The phosphorylation status of proteins is directly note that we did not identify the most active compound,
controlled by kinase and phosphatase activities, but NSC 357756, as an active compound from the in vitro
other factors, such as growth factors, cytokines, or cel- screen in our previous studies [11, 12], because it was
lular stress, also influence protein phosphorylation lev- not a submicromolar in vitro inhibitor of Cdc25. Thus,
els. In addition, many proteins are subject to activation the cell-based assay detected a compound that was
and deactivation by multiple kinases and phosphatases. active in whole cells, even though it was not one of the
For example, Erk dephosphorylation has been described most potent inhibitors of Cdc25 or MKP-3. The data
for a number of MAPK phosphatases and the serine/ suggest that both approaches, namely in vitro high-
throughput screening and target-based cellular assays,threonine phosphatase, PP2A. Thus, while protein phos-
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(DMEM) containing 10% fetal bovine serum (FBS, HyClone, Logan,should be used as complementary prioritization tools in
UT) and 1% penicillin-streptomycin (Life Technologies, Inc., Rock-the early drug discovery process.
ville, MD) in a humidified atmosphere of 5% CO2 at 37C.
Significance Cell-Based Screen
NIH 3T3 cells (2000 cells per well) were plated in the wells of colla-
High-throughput screening has become a main com- gen-coated 96-well darkwell plates (Packard ViewPlate) and allowed
to attach overnight. Cells were treated for 20 min with compounds,ponent of contemporary drug discovery. Many of the
fixed with 3.7% formaldehyde in PBS, and permeabilized with PBS/high-throughput screens used today are based on in
Triton X-100. Cells were stained with Hoechst 33342 fluorescentvitro assays, which have the advantage of being ultra-
dye to visualize nuclei. Phospho-Erk immunoreactive cells werehigh-throughput but do not take into consideration
visualized by staining with a phospho-specific Erk antibody followed
other parameters, for example, physicochemical prop- by an Alexa Fluor 488-conjugated secondary antibody (Molecular
erties that determine drug-like behavior such as cell Probes, Eugene, OR) using an XF100 filter set at excitation/emission
permeability. Furthermore, target-based screening wavelengths of 494/519 nm (Alexa 488) and 350/461 nm (Hoechst),
respectively. Plates were analyzed by automated image analysisassays may not be predictive of drug effect within the
on the ArrayScan II system (Cellomics, Pittsburgh, PA) using thecontext of the whole cell. We therefore investigated
previously described cytoplasm-to-nuclear translocation algorithmthe utility of a cell-based, high-content screening pro-
[2, 21]. The algorithm is based on measurements of phospho-Erk
cess, which generated information about the content fluorescence intensity within a nuclear mask defined by Hoechst
and spatial regulation of multiple macromolecules in 33342 staining (referred to as “cytonuclear intensity”) and within a
individual cells, to select for compounds with cellular cytoplasmic region defined by a set of concentric circles placed
around the nuclear mask (referred to as “cytoring intensity”) [21].activity. We chose as targets dual-specificity phospha-
Both cytonuclear and cytoring intensities were normalized to thetases (DSPases), which have a critical role in the regu-
total cytonuclear or cytoring area and expressed as average inten-lation of many signaling pathways including mitogen-
sity per pixel. Cytoplasmic-to-nuclear difference values were calcu-activated protein kinase (MAPK) and cyclin-dependent lated by subtracting the average cytoring intensity per pixel from
kinase (Cdk) activation. Several DSPases have been the average cytonuclear intensity per pixel.
shown to have oncogenic properties, but small mole- Compounds were analyzed as single data points on two separate
plates. Each plate contained negative control wells that did notcule inhibitors of DSPases with cellular activity are
receive primary antibody, four wells treated with vehicle alone, andlacking. We analyzed the NCI Diversity Set, a chemi-
four wells treated with Compound 5 (NSC 672121, 10 M) as acally diverse compound library, for phospho-Erk nu-
positive internal control.clear accumulation in intact mammalian cells, fol-
lowed by in vitro analysis of antiphosphatase activity Western Blotting
using recombinant enzymes. The assay enriched sub- NIH 3T3 cells were plated in 100 mm tissue culture dishes, exposed
stantially for in vitro phosphatase inhibitors. One com- to compounds for 20 min, harvested by trypsinization, and lysed.
Cell lysates were resolved on 4%–20% SDS-PAGE gels and trans-pound, namely NSC 357756, inhibited the Erk-specific
ferred to nitrocellulose membranes (Protran, Schleicher & Schuell,DSPase MKP-3 both in vitro and in a newly developed
Keene, NH). Membranes were probed with anti-phospho-Erk andmultiparameter fluorescence-based assay designed
anti-Erk antibodies. Positive antibody reactions were visualized us-to specifically measure MKP-3 inhibition in intact cells.
ing peroxidase-conjugated secondary antibodies (Jackson Immu-
Furthermore, NSC 357756 had in vivo antitumor activ- noResearch, West Grove, PA) and an enhanced chemiluminescence
ity in a variety of mouse models. The data suggest detection system (Renaissance, NEN, Boston, MA) according to
that a cellular assay for Erk phosphorylation, coupled manufacturer’s instructions. For quantitation of protein expression
levels, X-ray films were scanned on a Molecular Dynamics personalwith a chemical complementation strategy, may be a
SI densitometer and analyzed using the ImageQuant software pack-powerful tool in the discovery of lead structures for
age (Ver. 4.1, Molecular Dynamics, Sunnyvale, CA).novel, cell-active DSPase inhibitors.
In Vitro Phosphatase AssaysExperimental Procedures
Full-length MKP-3 and Cdc25B2 were expressed as His6-tagged
fusion proteins from a pET21a vector. The catalytic domain ofReagents
Cdc25A (amino acids 336–523) was subcloned into a pET21a vectorCompound 5 (NSC 672121, (2-(2-mercaptoethanol)-3-methyl-1,4-
as previously described [30]. Full-length VHR and PTP1B were ex-naphthoquinone) has been described previously [27]. The NCI Diver-
pressed as GST fusion proteins from a pGEX2T vector as describedsity Set was provided by Daniel W. Zaharevitz (National Cancer
[31]. GST and His6-tagged fusion proteins were purified from E. coliInstitute, Rockville, MD) and has been described elsewhere [11].
using standard methodology. Phosphatase inhibition studies wereMouse monoclonal anti-phospho-Erk (E10), rabbit polyclonal phos-
performed using a fluorescence-based 96-well microtiter platepho-Erk, and rabbit polyclonal pan-Erk antibodies were from Cell
assay with O-methyl fluorescein diphosphate (OMFP) as previouslySignaling Technology (Beverly, MA). Secondary antibodies were
described [11, 31].Alexa Fluor 488-conjugated goat anti-mouse, Alexa Fluor 546-conju-
gated goat anti-rabbit IgG (Molecular Probes, Eugene, OR), and
Analysis of Phospho-Erk Levels in MKP-3 ExpressingHRP-conjugated goat anti-rabbit IgG and goat-anti mouse IgG
and Nonexpressing HeLa Cell Subpopulations(Jackson ImmunoResearch, West Grove, PA). cDNA encoding myc-
HeLa cells (5000) were plated in the wells of a collagen-coated 384-tagged MKP-3 (PYST-1) in a pSG5 mammalian expression vector
well plate (Falcon Biocoat) and allowed to attach overnight. Cells[28, 29] was a gift from Dr. Stephen Keyse (IRCF, Dundee, UK).
were transfected with MKP-3 or EGFP cDNAs (100 ng/well) andThe bacterial expression vector for His6-MKP-3 was a gift from Dr.
Lipofectamine 2000 (Invitrogen, Carlsbad, CA; 1 l per 0.4 g DNA)Zhong-Yin Zhang (Albert Einstein College of Medicine, Bronx, NY).
in OPTIMem reduced serum medium as per manufacturer’s instruc-The pEGFP-C1 expression vector was from Clontech (Palo Alto,
tions. Four hours after transfection, complexes were removed andCA).
fresh medium containing 10% FBS was added. Eighteen hours later,
cells were treated in quadruplicate wells for 15 min with TPA orCell Culture
mixtures of TPA and phosphatase inhibitors, fixed, and immuno-NIH 3T3 and HeLa cells were obtained from ATCC (Manassas, VA)
and were maintained in Dulbecco’s Minimum Essential Medium stained with a mixture of anti-phospho-Erk (1:200 dilution, Cell Sig-
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naling Technology, Beverly, MA) and anti-c-myc (1:100 dilution, specificity phosphatases as targets for antineoplastic agents.
Nat. Rev. Drug Discov. 1, 961–976.Santa Cruz Biotechnology, Santa Cruz, CA) antibodies as described
above except that a 1 hr blocking step in PBS containing 10% 7. Galaktionov, K., Lee, A.K., Eckstein, J., Draetta, G., Meckler,
J., Loda, M., and Beach, D. (1995). CDC25 phosphatases asgoat serum and 1% BSA was included before addition of primary
antibodies. Positive phospho-Erk and c-myc-MKP-3 signals were potential human oncogenes. Science 269, 1575–1577.
8. Magi-Galluzzi, C., Mishra, R., Fiorentino, M., Montironi, R., Yao,visualized with Alexa-546 (phospho-Erk) and Alexa-488 (c-myc)-
conjugated secondary antibodies, respectively. Control conditions H., Capodieci, P., Wishnow, K., Kaplan, I., Stork, P.J., and Loda,
M. (1997). Mitogen-activated protein kinase phosphatase 1 isomitting Alexa-546 secondary antibody were included on each plate
to assess nonspecific phospho-Erk background staining. All stain- overexpressed in prostate cancers and is inversely related to
apoptosis. Lab. Invest. 76, 37–51.ing steps were carried out on a Biomek 2000 laboratory automation
workstation (Beckman-Coulter, Inc., Fullerton, CA). 9. Wang, H., Cheng, Z., and Malbon, C.C. (2003). Overexpression
of mitogen-activated protein kinase phosphatases MKP1,Plates were analyzed by three-channel multiparametric analysis
for phospho-Erk and c-myc-MKP-3 intensities in an area defined MKP2 in human breast cancer. Cancer Lett. 191, 229–237.
10. Denkert, C., Schmitt, W.D., Berger, S., Reles, A., Pest, S.,by nuclear staining using the general screening application on the
Siegert, A., Lichtenegger, W., Dietel, M., and Hauptmann, S.ArrayScan II (Cellomics, Pittsburgh, PA). Images were acquired in
(2002). Expression of mitogen-activated protein kinase phos-three independent channels using an Omega XF57 filter set at excita-
phatase-1 (MKP-1) in primary human ovarian carcinoma. Int. J.tion/emission wavelengths of 350/461 nm (Hoechst), 494/519 nm
Cancer 102, 507–513.(Alexa 488), and 556/573 nm (Alexa 546). Approximately 4000 indi-
11. Lazo, J.S., Aslan, D.C., Southwick, E.C., Cooley, K.A., Ducruet,vidual cells were analyzed for phospho-Erk and c-myc-MKP-3 or
A.P., Joo, B., Vogt, A., and Wipf, P. (2001). Discovery and biologi-GFP intensities. For each condition, the percentage of MKP-3 (GFP)-
cal evaluation of a new family of potent inhibitors of the dualexpressing cells was determined from FITC (Alexa-488) intensity
specificity protein phosphatase Cdc25. J. Med. Chem. 44, 4042–distribution histograms, setting appropriate gates for MKP-3 (GFP)-
4049.positive and MKP-3 (GFP)-negative cells. Phospho-Erk levels were
12. Lazo, J.S., Nemoto, K., Pestell, K.E., Cooley, K., Southwick,then averaged in MKP-3 expressing and nonexpressing subpopula-
E.C., Mitchell, D.A., Furey, W., Gussio, R., Zaharevitz, D.W.,tions. Large positive differences in phospho-Erk intensities between
Joo, B., et al. (2002). Identification of a potent and selectivethe two subpopulations indicated lower levels of phospho-Erk in
pharmacophore for Cdc25 dual specificity phosphatase inhibi-MKP-3-expressing cells compared with nonexpressing cells. Low
tors. Mol. Pharmacol. 61, 720–728.differences indicated similar levels of phospho-Erk in both cell sub-
13. Taing, M., Keng, Y.F., Shen, K., Wu, L., Lawrence, D.S., andpopulations. Negative differences were a result of spectral overlap
Zhang, Z.Y. (1999). Potent and highly selective inhibitors of thebetween the two fluorophores, resulting in an elevated background
protein tyrosine phosphatase 1B. Biochemistry 38, 3793–3803.signal in the red channel caused by green fluorescence emission.
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